

## RESEARCH ARTICLE

# The role of small intestinal bacterial overgrowth and false positive diagnosis of lactose intolerance in southwest Hungary—A retrospective observational study

Péter Varjú<sup>1,2</sup>, Birgit Ystad<sup>2</sup>, Noémi Gede<sup>1</sup>, Péter Hegyi<sup>1,2,3</sup>, Dániel Pécsi<sup>1,2</sup>, József Czimmer<sup>1,2\*</sup>

**1** Institute for Translational Medicine, Szentágotthai Research Centre, Medical School, University of Pécs, Pécs, Hungary, **2** Division of Gastroenterology, First Department of Medicine, Medical School, University of Pécs, Pécs, Hungary, **3** Hungarian Academy of Sciences-University of Szeged, Momentum Gastroenterology Multidisciplinary Research Group, Szeged, Hungary

\* [czimmer.jozsef@pte.hu](mailto:czimmer.jozsef@pte.hu)



## OPEN ACCESS

**Citation:** Varjú P, Ystad B, Gede N, Hegyi P, Pécsi D, Czimmer J (2020) The role of small intestinal bacterial overgrowth and false positive diagnosis of lactose intolerance in southwest Hungary—A retrospective observational study. PLoS ONE 15 (5): e0230784. <https://doi.org/10.1371/journal.pone.0230784>

**Editor:** Elizabeth S. Mayne, University of Witwatersrand/NHLS, SOUTH AFRICA

**Received:** June 10, 2019

**Accepted:** March 9, 2020

**Published:** May 8, 2020

**Copyright:** © 2020 Varjú et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the paper and its Supporting Information files.

**Funding:** This work was funded by: Emberi Erőforrás Fejlesztési Operatív Program (EFOP), EFOP-3.6.2-16-2017-0006 and EFOP-3.6.3-VEKOP (Versenyképes Közép-Magyarország Operatív Program) -16-2017-00009. The funders had no role in study design, data collection and analysis,

## Abstract

### Background

Lactose intolerance is a frequent gastrointestinal disease affecting 47% of the Eastern European population. Small intestinal bacterial overgrowth (SIBO) leads to carbohydrate malabsorption and therefore to false results during lactose breath and tolerance tests.

### Objectives

We aimed to assess the prevalence of lactose maldigestion and intolerance in Hungary and to investigate the role of combined diagnostic method and testing for SIBO in reducing false results.

### Methods

We retrospectively analyzed data from 264 adult symptomatic patients who underwent 50g lactose breath and tolerance tests in parallel over a one-year period at our center. A  $\geq 20$  ppm elevation of  $H_2$  or less than 1.1 mmol/l rise of blood glucose was diagnostic for lactose maldigestion. Patients with maldigestion who had symptoms during the test were defined as lactose intolerant. Patients with an early ( $\leq 90$  min) significant ( $\geq 20$  ppm) rise of  $H_2$  during lactose and/or lactulose breath tests were determined to have SIBO. Patients with slow/rapid oro-cecal transit and inappropriate preparation before the test were excluded.

### Results

49.6% of the 264 patients had lactose maldigestion, and 29.5% had lactose intolerance. The most frequent symptom was bloating (22.7%), while 34.8% of the study population and 60% of the symptomatic patients had SIBO. In 9.1% and 9.8% of the patients, the lactose

decision to publish, or preparation of the manuscript.

**Competing interests:** The authors have declared that no competing interests exist.

**Abbreviations:** CI, confidence interval; HIV, human immunodeficiency virus; IBD, inflammatory bowel disease; IBS, irritable bowel syndrome; LBT, lactose breath test; LI, lactose intolerance; LM, lactose maldigestion; LTT, lactose tolerance test; SIBO, small intestinal bacterial overgrowth; OR, odds ratio.

breath and tolerance test alone gave false positive result compared with the combined method. SIBO was present in 75% of the false positives diagnosed with breath test only.

## Conclusions

The prevalence of lactose intolerance is lower in Hungary compared to the Eastern European value (29.5% vs 47%), so it is worth performing a population-based prospective analysis in this area. A combination of lactose breath and tolerance tests and the careful monitoring of results (with early H<sub>2</sub> rise, lactulose breath test, etc.) can decrease the false cases caused by e.g. SIBO.

## Introduction

Lactose intolerance (LI) is a clinical syndrome characterized by abdominal symptoms after ingestion of lactose-containing products caused by lactose maldigestion (LM) [1–3]. The most common cause of primary LM is adult-type hypolactasia [4, 5]. Acquired organic disorders (e.g. small intestinal bacterial overgrowth (SIBO), celiac disease, inflammatory bowel disease (IBD), and infectious enteritis (e.g. giardiasis)), can lead to both downregulation of lactase expression and reduction of absorptive capacity and therefore to secondary lactose malabsorption [4, 5]. Approximately 47% of the Eastern European population is affected; however, LI is more common in Asia, Africa, and South America. It affects males and females equally [2, 6]. The prevalence of LM increases with age, however, the LI symptoms decrease in elderly [7, 8]. Because of insufficient lactase activity, lactose can reach the large intestine, where it is fermented by colonic bacteria, gases (H<sub>2</sub>, CO<sub>2</sub>, and CH<sub>4</sub>), short-chain fatty acids, and other products that are formed there. Excessive gas production causes luminal distension and leads to different gastrointestinal symptoms. The most common complaints are abdominal pain and discomfort, bloating, flatulence, and diarrhea as with SIBO [1, 3, 9–11]. The diagnostic methods available for LM or LI are based on the lactose breath test (LBT), lactose tolerance test (LTT), genetic test, and assessment of lactase activity in jejunal biopsy specimens, the LBT and LTT being the most popular methods [4]. However, in most studies and at most centers, only one of the last two methods (LBT or LTT) is used, resulting in higher rates of incorrect diagnosis caused by SIBO, for example, which can lead to carbohydrate malabsorption and therefore to false positive results during the LBT and LTT. Moreover, in some patients with methanogenic microbiota (e.g. *Methanobrevibacter smithii*), the bacteria convert hydrogen to methane, leading to false negative LBT results [2]. Restricting lactose intake or replacing the lactase enzyme can alleviate unpleasant lactose-induced symptoms [2–5].

SIBO is a condition in which the small intestine is excessively colonized by aerobic and anaerobic bacteria. Normally, there are fewer than 10<sup>5</sup> bacteria per milliliter in the duodenal and jejunal part of the small intestine, with ileal counts reaching 10<sup>8</sup> per milliliter [12]. The prevalence of SIBO is unclear, depending on the population and the diagnostic test used. It is more frequent among the elderly due to reduced gastric acid secretion and medications causing hypomotility [13]. Disorders disturbing mucosal defense mechanisms can predispose one to SIBO, intestinal motility disorders and chronic pancreatitis being the most common causes [14–16]. Other etiological factors are motility disorders (diabetes mellitus, irritable bowel syndrome [IBS], use of narcotics, intestinal pseudo-obstruction, etc.), anatomic disorders (adhesions, strictures, diverticulosis, etc.), immunological disorders (e.g. HIV), and metabolic and systemic diseases (e.g. cirrhosis) [12, 17–19]. SIBO causes mucosal damage and altered motility

and therefore leads to complex malabsorption (of carbohydrate, fatty acids, proteins, and vitamins), diarrhea, bloating, flatulence, and abdominal discomfort [13, 20–23]. A diagnosis of this disease can be based on carbohydrate breath tests or on an assessment of bacterial concentration from the jejunal aspirate. Although jejunal aspirate culture is the gold standard method, it is not widely used due to its invasiveness, poor reproducibility, possible contamination, and patchy disease localization. Carbohydrate breath tests are simple, non-invasive, inexpensive, and therefore widely used [24–26]. The treatment comprises correction of the underlying cause, antibiotic therapy, and nutritional support (e.g. lactose-free diet, vitamin replacement, and correction of nutrient deficiencies). Rifaximine is effective in 80% of patients [27, 28]. Higher doses (1200 or 1600 mg/day) are more effective compared to standard ones (600 or 800 mg/day) [29]. The length of antibiotic therapy is not clearly defined. A single 7–10-day course can alleviate symptoms in most patients [30]. Repeated or continuous antibiotic therapy should be useful if symptoms recur [13]. The effectiveness of probiotics is inconclusive, and generally, they are not recommended in SIBO [18, 31].

In this single-center retrospective study, we aimed to assess the prevalence of LM and LI in southwest Hungary (Baranya County, except for the Mohács district, with a population of 317,000 people), to investigate the role of a combined diagnostic method (LBT and LTT) in improving diagnostic accuracy, and to show that parallel testing for SIBO could reduce false positive cases determined by LBT and/or LTT.

## Materials and methods

The key points of the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guideline [32] were followed in planning and reporting this study (S1 File). We retrospectively analyzed data from adult symptomatic patients who underwent the LBT and LTT in parallel at our center (Division of Gastroenterology, First Department of Medicine, University of Pécs) between 15 February 2016 and 14 February 2017. The LBT and LTT were carried out with 50g lactose (equal to the content of 1 liter of milk), H<sub>2</sub> levels were measured with Micro H<sub>2</sub> instrument (Micro Medical Limited, P.O. Box 6. Rochester, Kent ME1 2AZ ENGLAND). Before lactose ingestion, baseline end-alveolar H<sub>2</sub> and blood glucose levels were measured (0 min). Then patients drank the set amount of lactose dissolved in 250 ml water. After this process, end-alveolar H<sub>2</sub> and blood glucose levels were measured every 30 minutes over a three-hour period (in the case of glucose over a two-hour period). Depending on the clinical situation and patients' compliance, in clinically uncertain (but not in all) cases, a lactulose breath test with 10g lactulose was carried out to prove or reject the diagnosis of SIBO or slow oro-cecal transit [26]. A significant,  $\geq 20$  ppm elevation of H<sub>2</sub> level during the LBT and/or less than 1.1 mmol/l rise of blood glucose during the LTT was diagnostic for LM. Patients with negative LBT and LTT are lactose digesters. Patients with LM who had symptoms during the test were defined as lactose intolerant. Patients with an early ( $\leq 90$  min) significant ( $\geq 20$  ppm) rise of H<sub>2</sub> during the LBT and/or lactulose breath test were determined to have SIBO [26]. The diagnostic criteria of the different conditions are summarized in Table 1. For optimal preparation, patients stopped taking laxatives, antibiotics, and prokinetics, avoided high fiber-containing foods and fasted for 12 hours, avoided smoking and exercise for at least two hours before the test. Antiseptic mouthwash was not given routinely, only for those with high initial H<sub>2</sub> value ( $> 20$  ppm). We excluded patients with inappropriate preparation for the test (baseline H<sub>2</sub> level  $> 20$  ppm) and those with suspected rapid or slow oro-cecal transit (clinical symptoms of gastroparesis and a negative LBT with a positive LTT or no significant rise of H<sub>2</sub> during a 180-min lactulose breath test compared to the baseline value). We collected data on the baseline characteristics of the analyzed population (mean age, gender differences, and their

**Table 1. The summary of the different diagnostic criteria used in our study.**

<b>Lactose maldigester (LM)</b>	LBT: $\geq 20$ ppm elevation of H <sub>2</sub> compared to baseline level and/or LTT: $< 1.1$ mmol/l rise of blood glucose level compared to baseline value
<b>Normal lactose digestion</b>	Negative LBT ( $< 20$ ppm elevation of H <sub>2</sub> level) and Negative LTT ( $\geq 1.1$ mmol/l elevation of blood glucose)
<b>Lactose intolerance (LI)</b>	Lactose maldigesters, who had symptoms during the test period
<b>Small intestinal bacterial overgrowth (SIBO)</b>	Significant ( $\geq 20$ ppm) rise of H <sub>2</sub> during lactose and/or lactulose breath test, within 90 minutes
<b>Slow oro-cecal transit (excluded)</b>	Clinical symptoms of gastroparesis and a negative LBT with a positive LTT or no significant rise of H <sub>2</sub> during a 180-min lactulose breath test compared to the baseline value

LBT: lactose breath test; LTT: lactose tolerance test.

<https://doi.org/10.1371/journal.pone.0230784.t001>

correlation with the outcome measures), the diagnostic tests (baseline and maximum H<sub>2</sub> and glucose levels, time of glucose and H<sub>2</sub> peak, and the presence of LM), the presence and type of symptoms occurring during the test (abdominal pain, cramps, discomfort, bloating, diarrhea, nausea/vomiting, borborygmi, and other gastrointestinal symptoms, such as increased bowel motility, flatulence, belching, a sensation of fullness in the stomach, a burning sensation in the stomach, an increased sensation for defecation or headache [3, 33]), and the presence of LI and SIBO. The data collection and research were approved by the director of the Clinical Center and the director of the First Department of Medicine of the University of Pécs (Institutional Review Board), and the study process was carried out in accordance current laws and regulations (Case Number: PTE/98494/2018). All patient data were fully anonymized after the specific parameters necessary for our research were collected. However, our analysis was made retrospectively; therefore, we have not included patients' data who had refused scientific purpose data handling.


## Statistical analysis

Data were analyzed using SPSS 25.0 software. Means, standard deviation, minimum and maximum values, and relative frequency were calculated for descriptive statistics. The Pearson correlation, the Mann–Whitney test, and odds ratios (OR) with 95% confidence interval (CI) were used for other analyses. A p-value of less than 0.05 was accepted as statistically significant.

## Results

A total of 310 patients were assessed in the period noted above. Twenty-four of them were excluded because of inappropriate preparation and 22 (7.6% of the well-prepared patients) were ruled out because of slow oro-cecal transit, leaving 264 patients, 185 females (F: 70.1%), and 79 males (M: 29.9%), for statistical analysis. No patient had rapid transit in our study group. The mean age of the analyzed study group was 40.3 years (F: 40.6 years; M: 39.5 years).

Based on the LBT and/or LTT results, 49.6% (131/264) of the study population had LM (LBT and/or LTT positivity), as represented in Fig 1. Seventy-eight (78/131, 59.5%) of them had symptoms after lactose ingestion and were therefore defined as lactose intolerant (78/264, 29.5%, Fig 1). Combined positivity (LBT+LTT) was found in 30.7% (81/264) of the patients (see Fig 1). There was no significant difference between females and males in the prevalence of normal lactose digestion, LM, and LI ( $p > 0.05$ ). There was no significant correlation between



**Fig 1. Summary of the basic results in the analyzed study population.** A significant,  $\geq 20$  ppm elevation of H<sub>2</sub> level during LBT and/or less than 1.1 mmol/l rise of blood glucose during LTT were diagnostic for lactose maldigestion. Patients with negative LBT and LTT are lactose digesters. Patients with LM who had symptoms during the test were defined as lactose intolerant. Patients with an early ( $\leq 90$  min) significant ( $\geq 20$  ppm) rise of H<sub>2</sub> during LBT and/or lactulose breath test were defined to have SIBO. LBT: lactose breath test; LTT: lactose tolerance test; SIBO: small intestinal bacterial overgrowth.

<https://doi.org/10.1371/journal.pone.0230784.g001>


age and digester ( $p = 0.352$ ), maldigester ( $p = 0.352$ ), and LI ( $p = 0.098$ ) status. The basic results of the analyzed population are summarized in Fig 1. The gender-related results are represented in S1 Fig.

### Lactose maldigestion and intolerance based on the LBT

Based on the LBT only, 39.8% of the tested study population (105/264) were LM, and 73 of them (69.5%) had symptoms during the test; therefore, 27.7% (73/264) of the population was defined as lactose intolerant (see Fig 2). The majority (159/264, 60.2%) of the patients had a negative LBT, however; 13.8% (22/159) of them had symptoms after lactose ingestion, meaning that 8.3% (22/264) of the analyzed patients had symptoms without a positive test result, as represented in Fig 2. There was a weak negative correlation between age and baseline H<sub>2</sub> ( $p = 0.009$ ;  $r = -0.161$ ). There was no significant connection between gender, age, and LBT positivity (gender:  $p > 0.05$ ; age:  $p = 0.792$ ). The results are summarized in Fig 2.

### Lactose maldigestion and intolerance based on the LTT

Based on an analysis of the LTT alone measured in parallel, 40.5% of the same study population (107/264) were maldigesters and 65 of them (60.7%) had symptoms during the test. Therefore, 24.6% (65/264) of the population was defined as lactose intolerant (see Fig 2). The majority (157/264, 59.5%) of the patients had a negative LTT; however, 19.1% (30/157) of them had symptoms after lactose ingestion, meaning that 11.4% (30/264) of the analyzed patients had symptoms without a positive test result (Fig 2). Men had a significantly higher



**Fig 2. Summary of the results based separately on the LBT, LTT, and on the combination of them.** LBT: lactose breath test; LTT: lactose tolerance test.

<https://doi.org/10.1371/journal.pone.0230784.g002>


baseline ( $p < 0.001$ ) and maximum ( $p = 0.015$ ) glucose level. There was a moderate positive correlation between age and glucose levels (baseline:  $p < 0.001$ ;  $r = 0.338$ ; maximum:  $p < 0.001$ ;  $r = 0.222$ ). There was no significant connection between gender, age, and LTT positivity (gender:  $p > 0.05$ ; age:  $p = 0.378$ ). The results are summarized in Fig 2.

### Combined LHBT and LTT positivity

Combined positivity (LBT+LTT) was found in 30.7% (81/264) of the patients, 74% of them (60/81) had symptoms. Therefore, 22.7% (60/264) of the study population was lactose intolerant based on the combined results (see Fig 2). In the majority (183/264, 69.3%) of the population one or both tests were negative; however, 19.1% (35/183) of them had symptoms meaning that 13.3% (35/264) of the analyzed patients had symptoms without combined test positivity (Fig 2). The results are summarized in Fig 2.

### Clinical symptoms

Thirty-six percent (95/264) of the patients had symptoms after lactose ingestion (see Fig 1), bloating being the most frequent (60/264; 22.7%), as seen in Fig 3. There was no statistically significant difference between females and males in the presence of symptoms ( $p > 0.05$ ). Those who had nausea/vomiting were significantly older ( $p = 0.014$ ). Otherwise, there was no statistically significant correlation between age and symptoms ( $p = 0.204$ ). 12.8% (17/133) of the lactose digester patients (the LBT and LTT are negative) and 59.5% (78/131) of the maldigester patients (at least one of the tests is positive) had clinical symptoms (see Fig 4). Based on the latest meta-analysis conducted by our workgroup [34], we hypothesize that IBS may be a contributing factor in LI among lactose maldigesters. Figs 3 and 4 show the frequency of the different symptoms in the study population, and among lactose maldigesters/digesters and



**Fig 3. The frequency and distribution of different symptoms in the entire study population.** Other symptoms comprise increased bowel motility, flatulence, belching, sensation of fullness in the stomach, headache, burning sensation in the stomach, or increased sensation for defecation.

<https://doi.org/10.1371/journal.pone.0230784.g003>


lactose intolerant/tolerant patients. Female/male data regarding symptoms are represented in [S2 Fig](#).

### The role of SIBO

Approximately one-third (92/264; 34.8%) of the study population (see [Fig 1](#)) and 60% (57/95) of the symptomatic patients had SIBO based on the definition (see [Table 1](#)). There was no significant difference in the presence of SIBO between females and males (F: 68/185, 36.8%; M: 24/79, 30.4%,  $p > 0.05$ ); furthermore, there was no significant correlation between age and SIBO ( $p = 0.848$ ). SIBO patients had significantly higher maximum  $H_2$  levels ( $p < 0.001$ ), and they reached the  $H_2$  peak later ( $p < 0.001$ ). Moreover, they had lower maximum glucose levels ( $p < 0.001$ ), and LTT positivity was significantly more frequent in this patient group (OR = 5.833; 95% CI: 3.356–10.138). Symptoms were more common in SIBO patients compared to non-SIBO patients (OR = 5.743; 95% CI: 3.300–9.994), especially abdominal discomfort (OR = 3.201; 95% CI: 1.196–8.565), bloating (OR = 4.798; 95% CI: 2.606–8.833), diarrhea (OR = 6.443; 95% CI: 2.737–15.168), and other symptoms (OR = 5.825; 95% CI: 2.193–15.469).


In 90.9% (240/264) of the patients the LBT gave correct diagnosis (30.7% true positive: 81/264, 60.2% true negative: 159/264) of LM (or the lack of it) using combined LBT and LTT as reference. False positive results were found in 9.1% (24/264) of the cases; however, there are no false negatives in this setting (see [Fig 5](#)). LBT in this setting has 100% sensitivity, 86.9% specificity, 77.1% positive predictive value, and 100% negative predictive value. SIBO was found in 76.5% (62/81) of the true positive and in 75% (18/24) of the false positive patients.

In 90.2% (238/264) of the patients the LTT gave correct diagnosis (30.7% true positive: 81/264, 59.5% true negative: 157/264) of LM (or the lack of it) using combined LBT and LTT as



**Fig 4. The frequency and distribution of different symptoms among lactose digesters/maldigesters, and among lactose tolerant/intolerant patients.** A significant,  $\geq 20$  ppm elevation of H<sub>2</sub> level during LBT and/or less than 1.1 mmol/l rise of blood glucose during LTT were diagnostic for lactose maldigestion. Patients with negative LBT and LTT are lactose digesters. Patients with LM who had symptoms during the test were defined as lactose intolerant. Other symptoms comprise increased bowel motility, flatulence, belching, sensation of fullness in the stomach, headache, burning sensation in the stomach, or increased sensation for defecation.

<https://doi.org/10.1371/journal.pone.0230784.g004>



**Fig 5. The diagnostic accuracy of the LBT and LTT verified by the combined results of the tests.** LBT: lactose breath test; LTT: lactose tolerance test.

<https://doi.org/10.1371/journal.pone.0230784.g005>

reference. False positive results were found in 9.8% (26/264) of the cases; however, there are no false negatives in this setting (see Fig 5). Therefore, LTT has 100% sensitivity, 85.8% specificity, 75.7% positive predictive value, and 100% negative predictive value. SIBO was found in 76.5% (62/81) of the true positive, but surprisingly in 0% (0/26) of the false positive patients.

Based on these findings the combination of the LBT and LTT and the careful monitoring of results (with e.g. early H<sub>2</sub> rise, parallel performed lactulose breath test) can decrease false results caused by e.g. SIBO.

## Discussion

In this retrospective, single-center study, we analyzed the epidemiological characteristics of LI in southwest Hungary and assessed the role of combined diagnostic method and small intestinal bacterial overgrowth in the accuracy of the diagnosis.

LI is a relatively common problem in the white population, affecting approximately 47% of Eastern European adults [2, 6]. There are widely-used, inexpensive, non-invasive, diagnostic methods based on measurement of end-alveolar H<sub>2</sub> concentration (LBT) or blood glucose (LTT) [2–5]. The sensitivity and specificity of these tests are relatively high, but they depend on the ingested lactose dose (25g LBT: 82% and 95%; 25g LTT: 78% and 93%; 50g LBT: 92% and 83%; 50g LTT: 94% and 90%) [35, 36]. Other circumstances, such as SIBO, antibiotic usage, lung diseases, inappropriate preparation, and abnormal gastric emptying can influence their diagnostic accuracy. A combination of these tests and careful evaluation of the results can reduce the false positive or negative cases; however, in most studies, they are used separately [37].

The gold standard diagnostic method is the testing of lactase activity in duodenal and jejunal biopsy samples taken from the mucosa. However, due to the invasiveness, high costs, and patchy enzyme expression, it is less frequently performed compared to the tests noted above. Moreover, it should be considered that similar lactase activity in two patients might result in different LBT results due to the different activity and composition of the intestinal microbiota. There are several genes associated with lactase non-persistence (C/T\_13910 with CC genotype; G/A\_22018 with GG genotype), but the availability of genetic testing is variable, and its costs are relatively high. Moreover, the lactase non-persistence allele is not always associated with LM [2, 3, 5, 34]. A Hungarian study, published by Nagy et al., determined the applicability of the LBT in comparison with genetic screening (C/T\_13910). They found that 37% of the analyzed population had lactase non-persistence, which correlated well with positive LBT results in symptomatic children [38]. We found similar LBT positivity among symptomatic adults. Another retrospective study from Hungary, conducted by Buzás et al., also underlined that both genetic and breath tests are sufficiently accurate [39].

In this study, we presented epidemiological data on the prevalence of LM and LI in southwest Hungary, we analyzed the frequency of the most common symptoms, we demonstrated that combined analysis of LBT and LTT can improve diagnostic accuracy and the parallel testing for SIBO could reduce false cases caused for example by SIBO. It should also be mentioned that the study population had a very large female representation (185 vs 79); however, there were no statistically significant gender-related differences regarding LM, LI, LBT/LTT positivity, symptoms frequency, and prevalence of SIBO, which underlines the literature data in case of LI [2]. Moreover, despite the literature data [7, 8, 13], we did not find any age-related correlations in the outcomes mentioned above.

The limitations of our results should be considered for a correct interpretation, thus possibly influencing outcomes. Firstly, our results are based on a single-center retrospective medical database analysis. Secondly, we only analyzed the results in a one-year period; therefore, the number of enrolled patients is relatively low. Thirdly, the amount of ingested lactose can

influence the prevalence of LM and LI, and the frequency of symptoms. We used a relatively high dose of lactose and we did not perform blinded testing with placebo. Based on the retrospective character, follow-up after antibiotic treatment or low-lactose diet could not be performed to confirm the diagnosis of SIBO and LI based on symptom relief. Moreover, lactulose breath test was performed only in clinically uncertain cases, not on all patients. Therefore, the true diagnosis and prevalence of LI and SIBO could not be assessed correctly. Only patients with high initial end-alveolar H<sub>2</sub> concentration got antiseptic mouthwash. Another significant limitation is that our study group comprises symptomatic patients referred to our clinic, thus potentially leading to sampling bias. It also should be considered that we did not measure methane levels in the end-alveolar gas samples to determine false negative LBT caused by methane producing bacteria. Based on the recent results [40] false negative LBT (5–15%) are mainly caused by methane production. Finally, the symptoms of the patients are subjective, thus possibly prompting inaccurate conclusions. Interpretation of patient-reported symptoms will differ between clinicians; therefore, standardized symptom definitions should have been used to minimize errors. According to the Oxford Centre for Evidence-Based Medicine 2011, the evidence level of our findings is level 3 [41].

## Conclusions

Based on our results, we can conclude that the prevalence of LI is lower in Hungary compared to the Eastern European value (29.5% vs 47%) and that it is worth performing a population-based prospective analysis in this area. During the provocation tests, 59.5% of lactose maldigesters had IBS-like symptoms (lactose intolerance), but the role of IBS in the background is unknown. SIBO was relatively common among symptomatic patients (60%), and this may influence the diagnostic accuracy of lactose maldigestion, based on the LBT and LTT as the only diagnostic test. Therefore, a combination of the LBT and LTT and careful monitoring of results may decrease the false cases caused by e.g. SIBO.

## Supporting information

**S1 File. STROBE checklist.** STROBE: Strengthening the Reporting of Observational Studies in Epidemiology [32].  
(DOCX)

**S1 Fig. The summary of the basic results among females/males.** A significant,  $\geq 20$  ppm elevation of H<sub>2</sub> level during LBT and/or less than 1.1 mmol/l rise of blood glucose during the LTT were diagnostic for lactose maldigestion. Patients with negative LBT and LTT are lactose digesters. Patients with LM who had symptoms during the test were defined as lactose intolerant. Patients with an early ( $\leq 90$  min) significant ( $\geq 20$  ppm) rise of H<sub>2</sub> during LBT and/or lactulose breath test were defined to have SIBO. LBT: lactose breath test; LTT: lactose tolerance test; SIBO: small intestinal bacterial overgrowth.  
(TIF)

**S2 Fig. The frequency and distribution of different symptoms among females/males.** Other symptoms comprise increased bowel motility, flatulence, belching, sensation of fullness in the stomach, headache, burning sensation in the stomach, or increased sensation for defecation.  
(TIF)

## Author Contributions

**Conceptualization:** Péter Varjú, Birgit Ystad, József Czimmer.

**Data curation:** Péter Varjú, Birgit Ystad.

**Formal analysis:** Péter Varjú, Noémi Gede.

**Funding acquisition:** Péter Hegyi.

**Investigation:** Péter Varjú, Birgit Ystad.

**Methodology:** Péter Varjú, Birgit Ystad, Dániel Pécsi, József Czimmer.

**Project administration:** József Czimmer.

**Resources:** Péter Hegyi.

**Software:** Noémi Gede.

**Supervision:** Péter Hegyi, Dániel Pécsi.

**Validation:** Péter Hegyi, Dániel Pécsi.

**Visualization:** Péter Varjú, Noémi Gede.

**Writing – original draft:** Péter Varjú, József Czimmer.

**Writing – review & editing:** Birgit Ystad, Noémi Gede, Péter Hegyi, Dániel Pécsi.

## References

1. Yang J, Fox M, Cong Y, Chu H, Zheng X, Long Y, et al. Lactose intolerance in irritable bowel syndrome patients with diarrhoea: the roles of anxiety, activation of the innate mucosal immune system and visceral sensitivity. *Aliment Pharmacol Ther.* 2014; 39(3):302–11. <https://doi.org/10.1111/apt.12582> PMID: 24308871
2. Misselwitz B, Butter M, Verbeke K, Fox MR. Update on lactose malabsorption and intolerance: pathogenesis, diagnosis and clinical management. *Gut.* 2019; 68(11):2080–91. <https://doi.org/10.1136/gutjnl-2019-318404> PMID: 31427404
3. Fassio F, Facioni M, Guagnini F. Lactose Maldigestion, Malabsorption, and Intolerance: A Comprehensive Review with a Focus on Current Management and Future Perspectives. *Nutrients.* 2018; 10(11):1599.
4. Borghini R, Donato G, Alvaro D, Picarelli A. New Insights In IBS-Like Disorders: Pandora's Box Has Been Opened; Review. *Gastroenterol Hepatol Bed Bench.* 2017; 10(2):79–89. PMID: 28702130
5. Szilagyi A, Ishayek N. Lactose intolerance, dairy avoidance, and treatment options. *Nutrients.* 2018; 10(12):1994.
6. Newcomer AD, McGill DB, Thomas PJ, Hofmann AF. Tolerance to lactose among lactase-deficient American Indians. *Gastroenterology.* 1978; 74(1):44–6. PMID: 336450
7. Rao DR, Bello H, Warren AP, Brown GE. Prevalence of lactose maldigestion. *Dig Dis Sci.* 1994; 39(7):1519–24. <https://doi.org/10.1007/BF02088058> PMID: 8026265
8. Di Stefano GV, Malservisi S., Strocchi A., Corazza GR, M. Lactose malabsorption and intolerance in the elderly. *Scand J Gastroenterol.* 2001; 36(12):1274–8. <https://doi.org/10.1080/003655201317097119> PMID: 11761016
9. Lomer M, Parkes G, Sanderson J. Lactose intolerance in clinical practice—myths and realities. *Aliment Pharmacol Ther.* 2008; 27(2):93–103. <https://doi.org/10.1111/j.1365-2036.2007.03557.x> PMID: 17956597
10. Suchy FJ, Brannon PM, Carpenter TO, Fernandez JR, Gilsanz V, Gould JB, et al. National institutes of health consensus development conference: Lactose intolerance and health. *Ann Intern Med.* 2010; 152(12):792–6. <https://doi.org/10.7326/0003-4819-152-12-201006150-00248> PMID: 20404261
11. Moritz K, Hemmer W, Jung P, Sesztak-Greinecker G, Götz M, Jarisch R, et al. Effect of a fructose and lactose elimination diet in patients with irritable bowel syndrome: A randomized double-blind placebo-controlled study. *J Gastroenterol Hepatol Res.* 2013; 2(10):833–9.
12. Meyers JS, Ehrenpreis ED, Craig RM. Small intestinal bacterial overgrowth syndrome. *Curr Treat Options Gastroenterol.* 2001; 4(1):7–14. <https://doi.org/10.1007/s11938-001-0042-2> PMID: 11177677
13. Quigley EM, Abu-Shanab A. Small intestinal bacterial overgrowth. *Inf Dis Clin.* 2010; 24(4):943–59.

14. Choung R, Ruff K, Malhotra A, Herrick L, Locke G III, Harmsen W, et al. Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture. *Aliment Pharmacol Ther.* 2011; 33(9):1059–67. <https://doi.org/10.1111/j.1365-2036.2011.04625.x> PMID: 21395630
15. Pimentel M. Evaluating a bacterial hypothesis in IBS using a modification of Koch's postulates: part 1. *Am J Gastroenterol.* 2010; 105(4):718. <https://doi.org/10.1038/ajg.2009.678> PMID: 20372119
16. Mackie RI, Sghir A, Gaskins HR. Developmental microbial ecology of the neonatal gastrointestinal tract. *Am J Clin Nutr.* 1999; 69(5):1035s–45s. <https://doi.org/10.1093/ajcn/69.5.1035s> PMID: 10232646
17. Vantrappen G, Janssens J, Hellemans J, Ghooys Y. The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine. *J Clin Invest.* 1977; 59(6):1158–66. <https://doi.org/10.1172/JCI108740> PMID: 864008
18. Bures J, Cyrany J, Kohoutova D, Förstl M, Rejchrt S, Kvetina J, et al. Small intestinal bacterial overgrowth syndrome. *World J Gastroenterol: WJG.* 2010; 16(24):2978. <https://doi.org/10.3748/wjg.v16.i24.2978> PMID: 20572300
19. Jones RM, Neish AS. Recognition of bacterial pathogens and mucosal immunity. *Cell Microbiol.* 2011; 13(5):670–6. <https://doi.org/10.1111/j.1462-5822.2011.01579.x> PMID: 21352463
20. Justus P, Fernandez A, Martin J, King C, Toskes P, Mathias J. Altered myoelectric activity in the experimental blind loop syndrome. *J Clin Invest.* 1983; 72(3):1064–71. <https://doi.org/10.1172/JCI111031> PMID: 6350361
21. Pai RK. A practical approach to small bowel biopsy interpretation: celiac disease and its mimics. *Semin Diagn Pathol.* 2014; 31(2):124–136. <https://doi.org/10.1053/j.semmp.2014.02.006> PMID: 24815938
22. Shindo K, Machida M, Koide K, Fukumura M, Yamazaki R. Deconjugation ability of bacteria isolated from the jejunal fluid of patients with progressive systemic sclerosis and its gastric pH. *Hepatogastroenterology.* 1998; 45(23):1643–50. PMID: 9840121
23. Sherman P, Lichtman S. Small bowel bacterial overgrowth syndrome. *Dig Dis.* 1987; 5(3):157–71. <https://doi.org/10.1159/000171170> PMID: 3311488
24. Fan X, Sellin J. Small intestinal bacterial overgrowth, bile acid malabsorption and gluten intolerance as possible causes of chronic watery diarrhoea. *Aliment Pharmacol Ther.* 2009; 29(10):1069–77. <https://doi.org/10.1111/j.1365-2036.2009.03970.x> PMID: 19222407
25. Khoshini R, Dai S-C, Lezcano S, Pimentel M. A systematic review of diagnostic tests for small intestinal bacterial overgrowth. *Dig Dis Sci.* 2008; 53(6):1443–54. <https://doi.org/10.1007/s10620-007-0065-1> PMID: 17990113
26. Rezaie A, Buresi M, Lembo A, Lin H, McCallum R, Rao S, et al. Hydrogen and methane-based breath testing in gastrointestinal disorders: the North American consensus. *Am J Gastroenterol.* 2017; 112(5):775. <https://doi.org/10.1038/ajg.2017.46> PMID: 28323273
27. Pimentel M. Review of rifaximin as treatment for SIBO and IBS. *Expert Opin Investig Drugs.* 2009; 18(3):349–58. <https://doi.org/10.1517/13543780902780175> PMID: 19243285
28. Peralta S, Cottone C, Doveri T, Almasio PL, Craxi A. Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with Rifaximin. *World J Gastroenterol: WJG.* 2009; 15(21):2628. <https://doi.org/10.3748/wjg.15.2628> PMID: 19496193
29. Scarpellini E, Gabrielli M, Lauritano CE, Lupascu A, Merra G, Cammarota G, et al. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. *Aliment Pharmacol Ther.* 2007; 25(7):781–6. <https://doi.org/10.1111/j.1365-2036.2007.03259.x> PMID: 17373916
30. Banwell J, Sherr H. Effect of bacterial enterotoxins on the gastrointestinal tract. *Gastroenterology.* 1973; 65(3):467–97. PMID: 4364400
31. Quigley EM, Quera R. Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics. *Gastroenterology.* 2006; 130(2):S78–S90.
32. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening of Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Ann Intern Med.* 2007; 147(8):573–7. <https://doi.org/10.7326/0003-4819-147-8-200710160-00010> PMID: 17938396
33. Matthews SB, Waud J, Roberts AG, Campbell AK. Systemic lactose intolerance: a new perspective on an old problem. *Postgrad Med J.* 2005; 81(953):167–73. <https://doi.org/10.1136/pgmj.2004.025551> PMID: 15749792
34. Varjú P, Gede N, Szakács Z, Hegyi P, Cazacu IM, Pécsi D, et al. Lactose intolerance but not lactose maldigestion is more frequent in patients with irritable bowel syndrome than in healthy controls: A meta-analysis. *Neurogastroenterol Motil.* 2018:e13527. <https://doi.org/10.1111/nmo.13527> PMID: 30560578
35. Storhaug CL, Fosse SK, Fadnes LT. Country, regional, and global estimates for lactose malabsorption in adults: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol.* 2017; 2(10):738–46. [https://doi.org/10.1016/S2468-1253\(17\)30154-1](https://doi.org/10.1016/S2468-1253(17)30154-1) PMID: 28690131

36. Marton A, Xue X, Szilagyi A. Meta-analysis: the diagnostic accuracy of lactose breath hydrogen or lactose tolerance tests for predicting the North European lactase polymorphism C/T-13910. *Aliment Pharmacol Ther.* 2012; 35(4):429–40. <https://doi.org/10.1111/j.1365-2036.2011.04962.x> PMID: 22211845
37. Hammer HF, Högenauer C. Lactose intolerance: Clinical manifestations, diagnosis, and management. Available from: [www.uptodate.com](http://www.uptodate.com)
38. Nagy D, Bogacsi-Szabo E, Varkonyi A, Csanyi B, Czibula A, Bede O, et al. Prevalence of adult-type hypolactasia as diagnosed with genetic and lactose hydrogen breath tests in Hungarians. *Eur J Clin Nutr.* 2009; 63(7):909–12. <https://doi.org/10.1038/ejcn.2008.74> PMID: 19156157
39. Buzás G, Fodor F, Csókay B. Accuracy of lactase gene C/T-13910 polymorphism and hydrogen breath test in a gastroenterology outpatient clinic: a retrospective study. *Orv Hetil.* 2016; 157(25):1007–12. <https://doi.org/10.1556/650.2016.30462> PMID: 27287841
40. de Lacy Costello B, Ledochowski M, Ratcliffe NM. The importance of methane breath testing: a review. *J Breath Res.* 2013; 7(2):024001. <https://doi.org/10.1088/1752-7155/7/2/024001> PMID: 23470880
41. Medicine OCfE-B. OCEBM Levels of Evidence Working Group. The Oxford 2011 levels of evidence. 2011. Available from: <http://www.cebm.net/index.aspx?o=5653>.